# Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

> **NCT07712757** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nuvation Bio Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation
- Astrocytoma IDH Mutant Grade 2
- Oligodendroglioma
- Oligodendroglioma IDH-mutant and 1p/19q-codeleted
- IDH-mutant Gliomas

## Interventions

- **DRUG:** Safusidenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07712757
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-03
- **Primary completion:** 2029-05
- **Final completion:** 2032-03
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712757, "Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*